Ne-peptidni antagonist NPS receptora, SHA-68, blokira NPS dejstvo kod životinja i proizvodi anksiogene efekte.[13] Nekoliko peptidnih agonista u antagonista izvedenih iz NPS je takođe poznato.[14][15][16][17][18]
Peptidna sekvenca
Sekvence neuropeptida S u nekoliko životinjskih vrsta:
vrsta
sekvenca
molekulska težina
čovek
SFRNGVGTGMKKTSFQRAKS
2187.5
pacov
SFRNGVGSGVKKTSFRRAKQ
2210.5
miš
SFRNGVGSGAKKTSFRRAKQ
2182.5
pas, šimpanza
SFRNGVGTGMKKTSFRRAKS
2215.6
kokoška
SFRNGVGSGIKKTSFRRAKS
2183.5
konsenzus
SFRNGVGxGXKKTSFxRAKx
N/A
Literatura
^Xu YL, Gall CM, Jackson VR, Civelli O, Reinscheid RK (2007). „Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain”. The Journal of Comparative Neurology. 500 (1): 84—102. PMID17099900. doi:10.1002/cne.21159.
^Reinscheid RK, Xu YL (2005). „Neuropeptide S and its receptor: a newly deorphanized G protein-coupled receptor system”. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 11 (6): 532—8. PMID16282594. doi:10.1177/1073858405276405.
^Reinscheid RK (2008). „Neuropeptide S: anatomy, pharmacology, genetics and physiological functions”. Results and Problems in Cell Differentiation. 46: 145—58. PMID18204825. doi:10.1007/400_2007_051.
^Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O (2004). „Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects”. Neuron. 43 (4): 487—97. PMID15312648. doi:10.1016/j.neuron.2004.08.005.
^Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, Guerrini R, Calò G (2008). „Anxiolytic-like effect of neuropeptide S in the rat defensive burying”. Peptides. 29 (12): 2286—91. PMID18793688. doi:10.1016/j.peptides.2008.08.014.
^Roth AL, Marzola E, Rizzi A, Arduin M, Trapella C, Corti C, Vergura R, Martinelli P, Salvadori S, Regoli D, Corsi M, Cavanni P, Caló G, Guerrini R (2006). „Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation”. The Journal of Biological Chemistry. 281 (30): 20809—16. PMID16720571. doi:10.1074/jbc.M601846200.
^Camarda V, Trapella C, Calo G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (2008). „Synthesis and biological activity of human neuropeptide S analogues modified in position 2”. Journal of Medicinal Chemistry. 51 (3): 655—8. PMID18181564. doi:10.1021/jm701204n.
^Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (2008). „Structure-activity study at positions 3 and 4 of human neuropeptide S”. Bioorganic & Medicinal Chemistry. 16 (19): 8841—5. PMID18793857. doi:10.1016/j.bmc.2008.08.073.